Invasive Bladder Cancer Clinical Trials

1 recruiting

Frequently Asked Questions

Common questions about Invasive Bladder Cancer clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 62 trials

Recruiting
Phase 3

Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer

Intermediate Risk Non-Muscle Invasive Bladder Cancer
Ferring Pharmaceuticals454 enrolled77 locationsNCT06510374
Recruiting
Phase 1

A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer

Non Muscle Invasive Bladder Cancer
Pfizer294 enrolled53 locationsNCT07206225
Recruiting
Phase 3

A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer

Non-muscle Invasive Bladder Cancer With Carcinoma in Situ
Ferring Pharmaceuticals250 enrolled64 locationsNCT06545955
Recruiting
Phase 1Phase 2

A Study of STM-416 Administered to Patients Undergoing TURBT for Recurrent Bladder Cancer

Non Muscle Invasive Bladder Cancer
SURGE Therapeutics75 enrolled10 locationsNCT05710848
Recruiting
Phase 1Phase 2

A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027)

Non Muscle Invasive Bladder Cancer
Merck Sharp & Dohme LLC32 enrolled13 locationsNCT06637423
Recruiting
Phase 2

A Trial of Durvalumab (MEDI4736) Plus Monalizumab in Non-Muscle-Invasive Bladder Cancer

Non Muscle Invasive Bladder CancerNon-Muscle Invasive Bladder Urothelial Carcinoma
John Sfakianos60 enrolled3 locationsNCT06503614
Recruiting
Not Applicable

A Study to Evaluate Efficacy and Safety of Hydeal Cyst® Intravesical Instillations in Patients Treated With Intravesical Chemotherapy or Immunotherapy in Non-muscle Invasive Bladder Cancer

Non Muscle Invasive Bladder Cancer
Istituto Oncologico Veneto IRCCS200 enrolled9 locationsNCT06245603
Recruiting

Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer 2

Bladder CancerNon-Muscle-Invasive Bladder Cancer (NMIBC)Recurrent Bladder Cancer
University of Washington408 enrolled6 locationsNCT07225127
Recruiting
Phase 2

Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC

High-risk Non-muscle Invasive Bladder Cancer
CG Oncology, Inc.325 enrolled65 locationsNCT06567743
Recruiting
Phase 2

Replacing Invasive Cystoscopy With Urine Testing for Non-muscle Invasive Bladder Cancer Surveillance

Non Muscle Invasive Bladder Cancer
White River Junction Veterans Affairs Medical Center240 enrolled8 locationsNCT05796375
Recruiting
Phase 2

Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer

Non Muscle Invasive Bladder Cancer
Protara Therapeutics131 enrolled61 locationsNCT05951179
Recruiting
Phase 1Phase 2

LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve

Non-muscle Invasive Bladder Cancer With Carcinoma in SituSuperficial Bladder Cancer
enGene, Inc.350 enrolled100 locationsNCT04752722
Recruiting
Phase 2

Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin

Non Muscle Invasive Bladder CancerHigh-grade Ta/ T1 Papillary Disease Bladder Cancer
Lepu Biopharma Co., Ltd.16 enrolled15 locationsNCT07283835
Recruiting

Sample Collection for Ongoing Research and Product Evaluation Study

Breast CancerLiver CancerPancreatic Cancer+9 more
Natera, Inc.9,600 enrolled1 locationNCT07318051
Recruiting
Not Applicable

Multi-parametric MRI in Patients Suspected for Muscle Invasive Bladder Cancer: a New Local Staging Paradigm

Bladder CancerMuscle Invasive Bladder Cancer
Radboud University Medical Center360 enrolled19 locationsNCT05779631
Recruiting
Not Applicable

Supporting Sexual Health in Bladder Cancer Patients: A Sequential Mixed-Methods Intervention Study

Muscle-Invasive Bladder CarcinomaBladder CancerNon-Muscle-Invasive Bladder Cancer (NMIBC)
University of Aarhus30 enrolled1 locationNCT07339761
Recruiting
Phase 4

Vesical Imaging-Reporting and Data System (VI-RADS) Followed by Photodynamic Trans-urethral Resection of Bladder Tumours (PDD-TURBT) to Avoid Secondary Resections (Re-TURBT) in Non-Muscle Invasive Bladder Cancers (NMIBCs)

Non Muscle Invasive Bladder CancerHigh Risk Non-Muscle Invasive Bladder Urothelial CarcinomaNon-Muscle Invasive Bladder Urothelial Carcinoma
University of Roma La Sapienza327 enrolled1 locationNCT05962541
Recruiting
Phase 2

A Phase II Trial of Bicalutamide in Patients Receiving Intravesical BCG for Non-muscle Invasive Bladder Cancer

Non Muscle Invasive Bladder Cancer
CHU de Quebec-Universite Laval160 enrolled7 locationsNCT05327647
Recruiting
Phase 2

Erdafitinib Monotherapy or in Combination With Cetrelimab in Muscle-invasive Bladder Cancer Patients With Fibroblast Growth Factor Receptor (FGFR ) Gene Alterations

Muscle Invasive Bladder Cancer
Spanish Oncology Genito-Urinary Group90 enrolled23 locationsNCT06511648
Recruiting
Phase 2

Neoadjuvant Zanidatamab + Tislelizumab + Chemotherapy for Selective Bladder Preservation in HER2-Positive MIBC

Muscle Invasive Bladder Cancer (MIBC)
Fujian Medical University Union Hospital25 enrolled12 locationsNCT07296705